Dr. Cameransi has over twenty-five years experience in specialty-pharma drug delivery. He has co-founded biotech/specialty companies which have been acquired by big pharma. At Lyotropic Therapeutics he was largely responsible for the FDA approval and Orphan Designation of Ryanodex(tm) for the treatment of the anesthetic induced crisis, Malignant Hyperthermia. Now at Mingowood, he is advancing the commercialization of acidic cannabinoids for unmet medical needs for ethical, FDA approvable products as well as various consumer markets.